Overview

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Status:
RECRUITING

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.

Phase:

PHASE1

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital, China

Collaborators:

AstraZeneca
Gracell Biotechnologies (Shanghai) Co., Ltd.